CN110944630A - Psychotropic agents and uses thereof - Google Patents
Psychotropic agents and uses thereof Download PDFInfo
- Publication number
- CN110944630A CN110944630A CN201880048781.8A CN201880048781A CN110944630A CN 110944630 A CN110944630 A CN 110944630A CN 201880048781 A CN201880048781 A CN 201880048781A CN 110944630 A CN110944630 A CN 110944630A
- Authority
- CN
- China
- Prior art keywords
- amisulpride
- disorder
- compound
- condition
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004089 psychotropic agent Substances 0.000 title description 2
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical class CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims abstract description 126
- 229960003036 amisulpride Drugs 0.000 claims abstract description 78
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 68
- -1 5-HT2a Chemical compound 0.000 claims abstract description 55
- 229940076279 serotonin Drugs 0.000 claims abstract description 21
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 17
- 239000013543 active substance Substances 0.000 claims abstract description 11
- 210000004556 brain Anatomy 0.000 claims abstract description 10
- 230000002159 abnormal effect Effects 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 96
- 238000000034 method Methods 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 102000005962 receptors Human genes 0.000 claims description 29
- 108020003175 receptors Proteins 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 20
- 201000000980 schizophrenia Diseases 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 9
- 208000020016 psychiatric disease Diseases 0.000 claims description 7
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 6
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 230000003042 antagnostic effect Effects 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 208000024196 oppositional defiant disease Diseases 0.000 claims description 3
- 208000022821 personality disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000007192 Childhood Schizophrenia Diseases 0.000 claims 1
- 208000031555 Treatment-Resistant Schizophrenia Diseases 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 208000029252 treatment-refractory schizophrenia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 28
- 230000004044 response Effects 0.000 abstract description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 54
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 31
- 229960003638 dopamine Drugs 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 238000009739 binding Methods 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 14
- NXKXZXNNWRYXRE-UHFFFAOYSA-N N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-4-(methylamino)benzamide Chemical compound CCN1CCCC1CNC(=O)C1=CC(=C(NC)C=C1OC)S(=O)(=O)CC NXKXZXNNWRYXRE-UHFFFAOYSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 229960001534 risperidone Drugs 0.000 description 11
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 229940025084 amphetamine Drugs 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000006742 locomotor activity Effects 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000164 antipsychotic agent Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000035699 permeability Effects 0.000 description 7
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 229960004170 clozapine Drugs 0.000 description 5
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N CHCl3 Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000000423 cell based assay Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000003420 antiserotonin agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 101150049660 DRD2 gene Proteins 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020400 Hostility Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 229940123502 Hormone receptor antagonist Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 241000920340 Pion Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000488908 Torreya Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 1
- 229960005123 cariprazine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003689 hormone receptor blocking agent Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 230000008433 psychological processes and functions Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Abstract
Amisulpride derivatives and the R enantiomer of amisulpride or pharmaceutical compositions thereof disclosed herein may be used alone or in combination with other CNS active agents to antagonize serotonin (e.g., 5-HT2a, 5-HT) in a subject7) A receptor. Amisulpride derivatives and the R enantiomer of amisulpride or pharmaceutical compositions thereof disclosed herein may be used alone or in combination with other CNS active agents for the treatment of one or more serotonin (e.g., 5-HT2a, 5-HT) responses in a subject7) Disorders of modulation of receptors. The amisulpride derivatives and the R enantiomer of amisulpride or pharmaceutical compositions thereof disclosed herein may be used alone or in combination with other CNS active agents for the treatment of one or more disorders associated with abnormal levels of serotonin in the brain.
Description
Priority requirement
This application claims the benefit of U.S. provisional application No. 62/508,263 filed on 2017, month 5, and day 18, which is incorporated herein by reference in its entirety.
Technical Field
The present invention relates generally to pharmaceutical compositions and methods for treating neuropsychiatric and/or psychological diseases or disorders.
Background
Schizophrenia is a chronic debilitating psychotic disorder affecting about 1% of the population. The disease is manifested by delusional behavior, dysfunctional thinking, agitated body movements, social withdrawal, and depression. Schizophrenic patients suffer from an extremely reduced quality of life, with a suicide potential ten times that of the general population.
Dopamine (especially D)2And D3) Antagonists are well known to ameliorate the symptoms of schizophrenia and have been used clinically for decades. In the past two decades, it has been recognized that the treatment of schizophrenia, like many psychiatric disorders, benefits from the involvement of a variety of receptors, including serotonin and adrenergic receptors. Even so, in fact, tens of approved drugs for the treatment of schizophrenia still have poor therapeutic efficacy in many patients. Side effects of existing agents include: movement disorders, loss of quiescence, weight gain, mood disorders, sexual dysfunction, sedation, orthostatic hypotension, excessive salivation, and (in some cases) agranulocytosis.
Amisulpride (4-amino-N- (((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide) was patented as an antipsychotic agent in 1981. Amisulpride selectively reacts with human dopamine D2(Ki2.8nM) and D3(Ki3.2nM) receptor subtype binding to D1,D4And D5Receptor subtypes do not have any affinity. With the spirit of typical and atypicalUnlike the inhibitory drugs, amisulpride exhibits low affinity for serotonin, α -epinephrine, histamine receptor subtype, muscarinic receptors, and sigma sites, although it has also been shown to bind low dibit numbers nM Ki5-HT of2BAnd HT7aReceptor binding. This ability of amisulpride to bind to the 5-HT receptor is believed to confer amisulpride the ability to treat the symptoms of depression (sometimes manifested in schizophrenic patients). Interestingly, amisulpride was not found to be on 5-HT as compared to other antipsychotics2aThe receptor has any activity.
Despite its unique activity, amisulpride has a low ability to cross the Blood Brain Barrier (BBB) to interact with receptors in the brain. In one study in 2014, amisulpride crossed a PAMPA membrane (P)e) The passive diffusion of (a) was the lowest among the 30 psychiatric drugs tested. Thus, the dose of amisulpride is very high, typically 400 to 800mg/d (although, up to 1,200 mg/day is not uncommon). Such high doses may adversely affect the subject being treated.
Summary of The Invention
Provided herein are novel amisulpride derivatives and pharmaceutical compositions thereof. In some examples, the amisulpride derivatives disclosed herein are dopamine and/or 5 serotonin antagonists. In some examples, the amisulpride derivatives disclosed herein have improved membrane (e.g., BBB) permeability as compared to amisulpride. In some examples, the amisulpride derivative may act as a Central Nervous System (CNS) dopamine and/or serotonin antagonist. These amisulpride derivatives have the structure of formula I, formula IA, formula IB or formula IC disclosed herein, including pharmaceutically acceptable salts thereof, and stereoisomers thereof (e.g., formula I-S, formula I-R, formula IA-S, formula IA-R, formula IB-S, formula IB-R, formula IC-S, and formula IC-R). Also provided herein are deuterated analogs of the amisulpride derivatives disclosed herein.
Also provided herein are serotonin (e.g., 5-HT2a, 5-HT)7) A method of delivering a receptor antagonist to the brain of a subject, comprising administering to the subject an amisulpride derivative disclosed herein or a pharmaceutical composition thereof; and serum in brainThe level of the hormone receptor antagonist is higher than amisulpride (racemic mixture) administered to the subject at comparable doses.
Also provided herein are methods for antagonizing serotonin (e.g., 5-HT2a, 5-HT) in a subject7) A method of receptor comprising administering to a subject amisulpride derivatives and/or R isomers of amisulpride or pharmaceutical compositions thereof as disclosed herein, alone or in combination with other CNS active agents.
Further provided herein are methods of treating a subject responsive to serotonin (e.g., 5-HT2a, 5-HT)7) A method of one or more conditions of modulation of a receptor comprising administering to a subject amisulpride derivatives and/or R isomers of amisulpride or pharmaceutical compositions thereof disclosed herein, alone or in combination with other CNS active agents.
Still further provided herein are methods for treating one or more disorders associated with abnormal serotonin levels in the brain comprising administering to a subject amisulpride derivatives and/or the R isomer of amisulpride or pharmaceutical compositions thereof disclosed herein, alone or in combination with other CNS active agents.
In response to serotonin (e.g., 5-HT2a, 5-HT)7) Examples of disorders of the receptor and/or disorders associated with abnormal serotonin levels in the brain include, but are not limited to, for example, psychiatric disorders. Examples of psychiatric disorders include, but are not limited to, schizophrenia, schizophrenic symptoms, schizoaffective disorders, bipolar disorder, depression, obsessive compulsive disorder, parkinson's disease, alzheimer's disease, oppositional defiant disorder, aggression, suicide, hostility, personality disorders, chronic fatigue syndrome, the major negative symptoms of schizophrenia, charbant syndrome, autism, and tourette's syndrome.
Brief description of the drawings
FIG. 1A: new object exploration data from sub-chronic PCP NOR studies in rats (± SEM, n ═ 10/group). The difference in discriminatory index ((time to explore new object-time to explore familiar object)/total exploration time) is described.
FIG. 1B: differential index data from a subchronic PCRNOR study in rats (n-10/group). The difference in discriminatory index ((time to explore new object-time to explore familiar object)/total exploration time) is described.
FIG. 2: total walking distance (over 1 hour) + SEM (n ═ 10/group). Compared with amphetamine, p is < 0.05 for all treatment groups.
FIG. 3: compounds 102, 103, 104, and amisulpride (101) with 5-HT7Binding of the receptor.
FIG. 4: amisulpride (ami) (rac)), the R enantiomer of amisulpride (ami (R)), and the S enantiomer of amisulpride (Amid (S)) and 5-HT7Binding of the receptor.
Detailed Description
As disclosed herein, 4-amino substituted derivatives of amisulpride (also referred to as 4-amino amisulpride derivatives and 4-amino substituted amisulpride derivatives) exhibit improved membrane (e.g., BBB) permeability and can be used to target related receptors in the brain at lower doses than amisulpride, with fewer side effects on the subject being treated than amisulpride. For example, 4-amino substituted amisulpride derivative compound 102 (also known as LB-102, N-methyl amisulpride and 4-methylamino substituted amisulpride derivatives) was prepared (examples 1 and 2) and showed unexpectedly high membrane permeability compared to amisulpride (example 4, 216.7 fold improvement at pH7.4, 87.5 fold improvement at pH 5). Stereoisomers of compound 102 (compound 103 and compound 104) (example 3), as well as other 4-aminoamisulpride derivative compounds 105 to 110, were also prepared. Furthermore, 4-amino substituted amisulpride derivatives were shown to react with dopamine D2Effective binding of receptors to various CNS receptors (examples 5-7). unexpectedly, 4-amino substituted amisulpride derivatives showed α 2 (e.g., α 2A, α 2B, and α 2C) receptor antagonism (Table 4, example 7), whereas amisulpride showed low affinity for α 2 receptors.4-amino substituted amisulpride derivatives showed 5-HT2aAntagonism of the receptor (Table 4, example 7), while amisulpride was not found in 5-HT2aThe receptor has any activity. Furthermore, compound 102 and compound 103 showed recovery of known object exploration in rats in a New Object Recognition (NOR) assay (example 8)The ability to distinguish between new and familiar objects is impaired. Normalized amphetamine overactivity in the amphetamine-induced locomotor activity (LMA) assay, compounds 102 and 103 were statistically superior to or indistinguishable from amisulpride (example 9). Further, stereoisomers of compound 102 (compound 103 and compound 104) are disclosed in combination with 5-HT7Unexpectedly different Ks were shown in receptor bindingiWherein K of R enantiomer (Compound 104)iAt 16nM, in contrast to the K of the S enantiomer (Compound 103)i(> 1,000nM (example 10). Unexpectedly, the R enantiomer of amisulpride showed an unexpectedly lower K than the S enantiomer of amisulpridei(FIG. 4).
4-amino-substituted amisulpride derivatives
Provided herein are amisulpride derivatives having the structure shown in formula I:
including pharmaceutically acceptable salts and stereoisomers thereof, wherein:
X and Z are the same or different and are independently selected from the group consisting of hydrogen, alkyl (branched or unbranched such as methyl, ethyl, n-propyl, isopropyl, n-butyl, and sec-butyl), alkenyl (branched or unbranched such as methyl, ethyl, n-propyl, isopropyl, n-butyl, and sec-butyl), alkynyl (branched or unbranched such as methyl, ethyl, n-propyl, isopropyl, n-butyl, and tert-butyl), cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl), cycloalkylalkyl (e.g., cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl), heterocyclyl, heterocyclylalkyl, aryl (e.g., phenyl, naphthyl, tetrahydronaphthyl, indanyl, and biphenyl), aralkyl (e.g., -CH, naphthyl, tetrahydronaphthyl, indanyl, and biphenyl), and the like2C6H5and-C2H5C6H5) Hetero aromatic hydrocarbonArylalkyl (e.g., -CH)2C6H4N and-C2H5C6H4N), and heteroaryl having one or two or three or more heterocyclic atoms (e.g., pyridine, pyrrole, furan, thiophene, or pyrimidine), optionally alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroarylalkyl, and heteroaryl are further substituted with one or more substituents selected from the group consisting of halogen such as chlorine, bromine, and fluorine, amine, hydroxyl, carboxylic acid, nitro, carbonyl, and other alkyl and aryl groups defined herein; with the proviso that at least one of X and Z is not hydrogen.
In some examples, the amisulpride derivative is a stereoisomer having the structure of formula I-S:
including pharmaceutically acceptable salts thereof, wherein Z, X, and R1As defined above in formula I.
In some examples, the amisulpride derivative is a stereoisomer having the structure of formula I-R:
including pharmaceutically acceptable salts thereof, wherein Z, X, and R1As defined above in formula I.
In some examples, the amisulpride derivative is a 4-amino substituted derivative of amisulpride having the structure of formula IA:
including pharmaceutically acceptable salts and stereoisomers thereof, and X and Z are as defined above in formula I.
In some examples, the 4-amino substituted derivative of amisulpride is a stereoisomer having the structure of formula IA-S:
including pharmaceutically acceptable salts thereof, and X and Z are as defined above in formula I.
In some examples, the 4-amino substituted derivative of amisulpride is an isomer having the structure of formula IA-R:
including pharmaceutically acceptable salts thereof, and X and Z are as defined above in formula I.
In some examples, the amisulpride derivative is a 4-amino substituted derivative of amisulpride having the structure of formula IB:
including pharmaceutically acceptable salts and stereoisomers thereof, and Z is as defined above for formula I, with the proviso that Z is not H.
In some examples, the 4-amino substituted derivative of amisulpride is a stereoisomer having formula IB-S:
including pharmaceutically acceptable salts thereof, and Z is as defined above in formula I, with the proviso that Z is not H.
In some examples, the 4-amino substituted derivative of amisulpride is a stereoisomer having the structure of formula IB-R:
including pharmaceutically acceptable salts thereof, and Z is as defined above in formula I, with the proviso that Z is not H.
In some examples, the amisulpride derivative has the structure of formula IC:
including pharmaceutically acceptable salts and stereoisomers thereof, and Z is as defined above in formula I, with the proviso that Z is not H.
In some examples, the amisulpride derivative is a stereoisomer having the structure of formula IC-S:
including pharmaceutically acceptable salts thereof, and Z is as defined above in formula I, with the proviso that Z is not H.
In some examples, the amisulpride derivative is a stereoisomer having the structure of formula IC-R:
including pharmaceutically acceptable salts thereof, and Z is as defined above in formula I, with the proviso that Z is not H.
In some examples, the amisulpride derivatives disclosed herein have greater membrane (e.g., BBB) permeability than amisulpride in some examples, the amisulpride derivatives disclosed herein are dopamine and/or serotonin and/or α 2 antagonists2And/or D3Receptor binding. In some examples, dopamine D is compared1,D4And/or D5The receptor, amisulpride derivatives disclosed herein, binds more selectively to dopamine D2And/or D3In some examples, the amisulpride derivatives disclosed herein are capable of interacting with dopamine and/or serotonin and/or α 2 receptors in the CNS.
Also provided herein are deuterated analogs of the amisulpride derivatives disclosed herein, wherein one or more hydrogens of the amisulpride derivative are replaced with deuterium. In some examples, one or more of the deuterated analogs are present at a level at least 100 times greater than the natural abundance level.
Provided herein are pharmaceutical compositions comprising one or more of the amisulpride derivatives and deuterated analogs thereof disclosed herein and a pharmaceutically acceptable carrier. In some examples, the pharmaceutical composition comprises one or more amisulpride derivatives that are substantially enantiomerically pure, and such pharmaceutical compositions are also referred to as substantially enantiomerically pure pharmaceutical compositions. In some examples, the term "substantially enantiomerically pure" refers to an enantiomeric purity of about 50% or greater, about 60% or greater, about 70% or greater, about 80% or greater, about 90% or greater, about 95% or greater, or about 98% or greater.
Also provided herein are methods of administering dopamine and/or serotonin (e.g., 5-HT)2a,5-HT7) And/or α 2 receptor antagonist, comprising administering to the subject one or more of the amisulpride derivatives and deuterated analogs thereof disclosed herein, or a pharmaceutical composition thereof, and dopamine and/or serotonin (e.g., 5-HT) in the brain2a,5-HT7) And/or α 2 receptor antagonist levels are higher than amisulpride (racemic mixture) administered to a subject at comparable doses.
Also provided herein are methods of antagonizing dopamine and/or serotonin (e.g., 5-HT) in a subject2a,5-HT7) And/or α 2 receptor, comprising administering to a subject one or more of the amisulpride derivatives disclosed herein and deuterated analogs thereof, the R enantiomer of amisulpride, or pharmaceutical compositions thereof, alone or in combination with a CNS active agent.
Also provided herein are methods for treating a subject responsive to dopamine and/or serotonin (e.g., 5-HT)2a,5-HT7) And/or α 2 receptors, comprising administering to a subject a therapeutically effective amount of one or more of the amisulpride derivatives and deuterated analogs thereof disclosed herein, the R enantiomer of amisulpride, or a pharmaceutical composition thereof, alone or in combination with other CNS active agents.
Provided herein are methods for treating one or more disorders associated with abnormal levels of dopamine and/or serotonin in the brain of a subject, comprising administering to the subject a therapeutically effective amount of one or more of the amisulpride derivatives and deuterated analogs thereof disclosed herein, the R enantiomer of amisulpride, or a pharmaceutical composition thereof. In some examples, the amisulpride derivative, deuterated analog, and/or pharmaceutical composition is substantially enantiomerically pure.
In some examples, the therapeutically effective amount of the amisulpride derivative, the R enantiomer of amisulpride, or the pharmaceutical composition thereof disclosed herein is less than the therapeutically effective amount of amisulpride. Thus, the methods disclosed herein may result in fewer adverse events to the subject being treated.
Responsive to dopamine and/or serotonin (e.g., 5-HT)2a,5-HT7) Examples of psychiatric disorders include, but are not limited to, schizophrenia, symptoms of schizophrenia, schizoaffective disorders, depression, obsessive compulsive disorders, Parkinson's disease, Alzheimer's disease, oppositional defiant disorder, aggressiveness, suicidality, hostility, personality disorders, autism, chronic fatigue syndrome, the primary negative symptoms of schizophrenia, Charles Banner syndrome, and Torreya.
As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, the term "cell" includes a plurality of cells, including mixtures thereof. Similarly, unless the context clearly indicates otherwise, the use of "a compound" in the preparation or treatment of a pharmaceutical formulation described herein includes the use of one or more compounds of the invention to effect such treatment or preparation.
As used herein, the term "comprising" is intended to mean that the compositions and methods include the recited elements, but not exclude other elements. Thus, a composition consisting essentially of the elements defined herein does not exclude trace contaminants from isolation and purification processes and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives and the like. Constitute "shall mean excluding trace elements in excess of other ingredients and the essential method steps for administering the compositions of the present invention. Examples defined by each transition term are within the scope of the present invention.
The term "alkyl" refers to a straight or branched hydrocarbon chain radical consisting only of carbon and hydrogen atoms, with no unsaturation. Unless otherwise specified, the term "alkyl" refers to a group having one, two, three, four, five, six, seven, or eight carbon atoms (e.g., one to six carbon atoms, or one to four carbon atoms) and is attached to the remainder of the molecule by a single bond. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, sec-butyl, n-pentyl, and sec-pentyl.
The term "alkenyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond, which may be straight or branched. Unless otherwise indicated, the term "alkenyl" refers to groups having 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, such as ethenyl, 1-propenyl, 2-propenyl (allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, and 2-butenyl.
The term "alkynyl" refers to a straight or branched chain hydrocarbyl radical having at least one carbon-carbon triple bond. Unless otherwise specified, the term "alkynyl" refers to groups having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 carbon atoms (e.g., 2 to 10 carbon atoms), such as ethynyl, propynyl, and butynyl.
The term "cycloalkyl" denotes non-aromatic mono-or polycyclic ring systems of 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
The term "cycloalkylalkyl" refers to a cycloalkyl group as defined above directly bonded to an alkyl group as defined above.
The term "aryl" refers to monocyclic or polycyclic aromatic radicals having 6 to 20 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl, indanyl, and biphenyl.
The term "arylalkyl" refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH2C6H5and-C2H5C6H5。
The term "heterocyclyl" refers to a non-aromatic 3-to 15-membered ring radical consisting of carbon atoms and at least one heteroatom selected from nitrogen, phosphorus, oxygen, and sulfur. The heterocyclic radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atoms may optionally be quaternized.
The term "heterocyclylalkyl" refers to a heterocyclyl group as defined above directly bonded to an alkyl group as defined above.
The term "heteroaryl" refers to an optionally substituted 5-14 membered aromatic ring having as ring atoms one or more heteroatoms selected from N, O, and S. Heteroaryl groups may be monocyclic, bicyclic or tricyclic ring systems. Examples of such heteroaryl ring radicals include, but are not limited to, oxazolyl, thiazolyl, imidazolyl, pyrrolyl, furyl, pyridyl, pyrimidinyl, pyrazinyl, benzofuryl, indolyl, benzothiazolyl, benzoxazolyl, carbazolyl, quinolinyl, and isoquinolinyl.
The term "heteroarylalkyl" refers to a heteroaryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH2C6H4N, and-C2H5C6H4N。
The term "subject" refers to a mammal, such as a domestic pet (e.g., a dog or cat) or a human. In some examples, the subject is a human.
The phrase "effective amount" refers to an amount sufficient to effect such treatment on a disease when administered to a subject or patient to treat the disease.
"treating" or "treating" includes (1) inhibiting the disease (e.g., arresting further development of the condition and/or symptom) in a subject or patient experiencing or presenting with the condition or symptom of the disease, (2) ameliorating the disease (e.g., reversing the condition and/or symptom) in a subject or patient experiencing or presenting with the condition or symptom of the disease, and/or (3) causing any measurable reduction in the disease in a subject or patient experiencing or presenting with the condition or symptom of the disease.
The term "pharmaceutically acceptable carrier" refers to a carrier that does not cause an allergic or other untoward reaction in the patient receiving the administration and is compatible with the other ingredients in the formulation. Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients or carriers appropriately selected for the intended form of administration and are in accordance with conventional pharmaceutical practice. For example, solid carriers/diluents include, but are not limited to, gums, starches (e.g., corn starch, pregelatinized starch), sugars (e.g., lactose, mannitol, sucrose, dextrose), cellulosic materials (e.g., microcrystalline cellulose), acrylates (e.g., polymethacrylates), calcium carbonate, magnesium oxide, talc, or mixtures thereof. The pharmaceutically acceptable carrier may further comprise minor amounts of auxiliary substances, such as wetting or emulsifying agents, preservatives or buffering agents, which enhance the shelf-life or effectiveness of the therapeutic agent.
The term "salt" as used herein is not limited as long as the salt is formed by a compound of the amisulpride derivative and is pharmaceutically acceptable; preferred examples of the salt include hydrohalide salts (e.g., hydrochloride, hydrobromide, hydroiodide, etc.), inorganic acid salts (e.g., sulfate, nitrate, perchlorate, phosphate, carbonate, bicarbonate, etc.), organic carboxylic acid salts (e.g., acetate, maleate, tartrate, fumarate, citrate, etc.), organic sulfonic acid salts (e.g., methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, camphorsulfonate, etc.), amino acid salts (e.g., aspartate, glutamate, etc.), quaternary ammonium salts, etc. In addition, hydrochloride, sulfate, methanesulfonate, acetate and the like are preferable as "pharmacologically acceptable salts" of the amisulpride derivatives disclosed herein.
The isomers (e.g., geometric isomers, optical isomers, rotamers, tautomers, etc.) of the amisulpride derivatives disclosed herein can be purified as single isomers using conventional separation methods, including, for example, recrystallization, optical resolution such as the diastereomeric salt method, enzymatic fractionation methods, various chromatographic methods (e.g., thin layer chromatography, column chromatography, glass chromatography, etc.).
Pharmaceutical formulations and routes of administration
The amisulpride derivatives and/or deuterated analogs thereof disclosed herein can be administered by a variety of routes including oral administration and injection (e.g., subcutaneous, intravenous, and intraperitoneal). Amisulpride derivatives disclosed herein can be prepared into pharmaceutical compositions for use in the disclosed methods. Such compositions are prepared according to acceptable Pharmaceutical procedures, such as those described in Remington's Pharmaceutical Sciences, 17 th edition, Alfonso R.Gennaro, Mac Publishing Company (Mack Publishing Company), Pennsylvania, 1985, which is incorporated herein by reference.
The amisulpride derivatives and/or deuterated analogs thereof disclosed herein can be administered orally in the form of solid or liquid dosage forms. In both cases, the amisulpride derivative compounds disclosed herein may be encapsulated in a material to protect them from the action of acids and other natural conditions that may inactivate the compounds. The amisulpride derivatives disclosed herein may be formulated as aqueous solutions, liquid dispersions, (ingestible) tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and tablets (wafers). Oral dosage forms may include excipients known in the art such as binders, disintegrants, flavoring agents, antioxidants, and preservatives. The liquid dosage form may include a diluent, such as saline or an aqueous buffer.
Amisulpride derivatives and/or deuterated analogs thereof disclosed herein can also be administered by injection. Formulations suitable for injection may include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The pharmaceutical composition may be sterile and may be a liquid to the extent that it is easily injectable. It may be stable under the conditions of manufacture and storage and may prevent the contaminating action of microorganisms such as bacteria and fungi. The pharmaceutically acceptable carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. For example, proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The action of microorganisms can be prevented by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, and ascorbic acid. In many cases, it will be preferable to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
Sterile injectable solutions can be prepared by incorporating the therapeutic compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Typically, dispersions are prepared by incorporating the therapeutic compound into a sterile vehicle that contains a base dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient (i.e., the therapeutic compound) plus any additional desired ingredient from a previously sterile-filtered solution thereof.
The actual dose of the compound administered to the subject may be determined by physical and physiological factors such as age, sex, weight, severity of the condition, type of disease to be treated, previous or concurrent therapeutic intervention, the subject's idiopathy and the route of administration. These factors can be determined by the skilled person. The practitioner responsible for administration will typically determine the concentration of the active ingredient in the composition and the appropriate dosage for the individual subject.
In one example, a daily dose of about 0.01mg/kg to about 100mg/kg is administered to a human subject.
Single or multiple doses of the compound are contemplated. The time interval required to deliver multiple doses can be determined by one of ordinary skill in the art using no more than routine experimentation. For example, two doses per day may be administered to a subject at about 12 hour intervals. In some examples, the compound is administered once daily.
The amisulpride derivatives or pharmaceutical compositions thereof disclosed herein may be administered by conventional regimens. As used herein, a conventional protocol refers to a predetermined specified period of time. The conventional schemes may include time periods of the same duration or time periods of different durations, so long as the schemes are predetermined. For example, a conventional regimen may involve dosing twice daily, every second day, every third day, every fourth day, every fifth day, every sixth day, weekly, monthly or any set number of days or weeks in between. Alternatively, the predetermined routine may involve dosing twice daily for the first week, followed by daily dosing for months. In other examples, the amisulpride derivatives disclosed herein or pharmaceutical compositions thereof provided by the invention may be administered orally, with or without timing dependent on food intake. Thus, for example, the medicament may be taken every morning and/or every evening, whenever the subject is or will be eating.
Combination therapy
In addition to being used as monotherapy, the amisulpride derivatives or pharmaceutical compositions thereof disclosed herein may also be used in combination therapy. Effective combination therapy can be achieved with a single pharmaceutical composition or pharmacological formulation comprising two agents administered simultaneously or two different pharmaceutical compositions or pharmacological formulations, wherein one composition comprises a compound of the invention and the other comprises a second agent. Alternatively, treatment may be preceded or followed by other agents and separated by a period of minutes to months.
The additional agent or agents may be selected from any agent or agents useful for treating a psychological disorder, such as any agent or agents useful for treating dopamine, serotonin, histamine, or glutamate imbalance and/or α 2 in one example, additional agents or agents may be useful for improving psychological function, such as antipsychotics, such as quetiapine, clonidine, replanole, lurasidone, olanzapine, risperidone, iloperidone, ziprasidone, clozapine, haloperidol, chlorpromazine, citalopram (citrlopram), escitalopram, paroxetine, fluoxetine, fluvoxamine, sertraline, venlafaxine, duloxetine, milnacipran, venlafaxine, vilazone, and combinations thereof.
Synthesis of amisulpride derivatives
The amisulpride derivatives disclosed herein of the present invention can be prepared from amisulpride (4-amino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide), which is readily available. The synthesis of amisulpride is described, for example, in us patent No. 4,401,822.
The following syntheses for preparing compounds of formula IB may be adapted to prepare other compounds of the invention, for example, compounds of formulae I, IA, and IC. The compounds of formula IB can be prepared by the following steps: (a) treating amisulpride with a mixture of a carboxylic acid and its corresponding anhydride to obtain the corresponding amide, (b) treating amisulpride with, for example, borane: a suitable reducing agent for dimethyl sulfide reduces the amide to an amine to form a compound of formula IB:
wherein Z is as defined above, and Z ═ C-R.
The reaction scheme is shown below:
Similarly, compounds of formula IA can be prepared by further substituting the corresponding group X for N-H in the corresponding compound of formula IB; the compounds of formula IC can be prepared by acylation of the corresponding aniline in the compound of formula IB and subsequent reduction.
Alternatively, amisulpride is reacted with N, N-dimethylformamide dimethyl acetal to provide the corresponding amide, followed by a reducing agent (e.g., NaBH)4,DMS:BH3Red-Al, and LiAlH4) Reduction to provide the corresponding 4-methylamino-substituted amisulpride derivative, whereby the 4-methylamino-substituted amisulpride derivative can be prepared.
Scheme 2.4 preparation of methylamino-substituted amisulpride derivatives
The stereoisomers of the amisulpride derivatives disclosed herein may be prepared analogously by using the corresponding stereoisomers of amisulpride as starting materials. For example, the synthesis of ((S) -4-amino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide can be performed as described in U.S. patent No. 6,169,094, which is incorporated herein by reference. The S isomer of amisulpride derivatives can be prepared using the S isomer of amisulpride (schemes 3 and 4). The R isomer of amisulpride derivatives can be similarly prepared using the R isomer of amisulpride.
Scheme 3. preparation of amisulpride derivatives (exemplified by the S-isomer)
Scheme 4.4 preparation of methylamino-substituted amisulpride derivatives (S-isomers)
When neither Z nor X of the amisulpride derivative of formula I is hydrogen, amisulpride derivatives (di-substituted 4-aminoamisulpride derivatives) can be prepared by two-step substitution of the 4-amino group. Firstly, as shown above, substituting a first substituent of Z or X for 4-amino to obtain a monosubstituted 4-amino amisulpride derivative; then carrying out secondary substitution on the 4-amino group of the mono-substituted 4-amino amisulpride derivative to obtain the required di-substituted 4-amino amisulpride derivative. See, for example, examples 3C and 3D.
Having described the invention with reference to examples and illustrative examples, those skilled in the art will appreciate that modifications may be made to the invention as described and illustrated without departing from the spirit and scope of the invention as disclosed in the specification. Examples are set forth to aid in understanding the invention, but are not intended to, and should not be construed to, limit its scope in any way. These examples do not include detailed descriptions of conventional methods. These methods are well known to those of ordinary skill in the art and are described in numerous publications. In addition, all references cited above and in the following examples are hereby incorporated by reference in their entirety as if fully set forth herein.
Examples of the present invention
Example 1: 4-carboxamide-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzene
Synthesis of formamide (Compound 1)
To a solution of 4-amino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (2g, 5.5mmol) in 20mL of formic acid at 5-10 deg.C was added acetic anhydride (0.68g, 6.6mmol) in portions. The reaction mixture was stirred at room temperature overnight and K was poured carefully into the flask at 5-10 deg.C2CO3In aqueous solution. Adding solid NaCl, and adding CHCl3The mixture is extracted. With Na2SO4The combined organic extracts were dried overnight and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using CHCl35-10% of MeOH to give 1.82g (83%) of a yellow gum.1HNMR(400MHz,CDCl3):δ1.1(t,3H,CH3),1.3(t,3H,CH3)1.6(br s,2H),1.7(br s,2H),1.9(brs,1H),2.3(br s,2H),2.7(br s,1H),2.9(br s,1H),3.2(q,2H),3.3(br s,1H),3.4(br s,1H),3.7(m,1H),4.1(s,3H,OCH3),8.4(br s,1H,NH),8.5(s,1H,Har),8.6(s,1H,Har) 8.7(s, 1H, CHO), 10.1(s, 1H, NH)18H27N3OsS]: 397.2, observed molar weight 398.1[ M + H ]+]。
Example 2: 4-methylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzene
Synthesis of formamide (Compound 102)
To a solution of 4-carboxamide-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (compound 1, 1.82g, 4.6mmol) in 80mL THF at 5-10 deg.C was added BH portionwise3·Me2S (1.09mL, 11.5 mmol). The reaction mixture was stirred at 60 ℃ for 3h and carefully quenched by MeOH (40 mL). The reaction mixture was acidified with 10% HCl (15mL) and the mixture was stirred at 60 ℃ overnight. The solvent is evaporated under reduced pressure and the aqueous residue is taken up with H2Diluted with O and basified with aqueous NaOH to pH 10. With CHCl3Extracting the mixture with Na2SO4The combined organic extracts were dried and evaporated. The residue was purified by column chromatography on silica gel using CHCl3Eluted with 5-10% MeOH, then purified by RP-HPLC using MeCN-H2Elution with an O + 0.1% TFA gradient. The fractions containing the target substance were partially evaporated under reduced pressure, basified to pH10 with aqueous NaOH solution and diluted with CH2C12And (4) extracting. The combined extracts were extracted with Na2SO4Dried and evaporated under reduced pressure to give the product as a white solid,after storage and standing, the mixture was solidified (0.93g, 53%).1H NMR(400MHz,CDCl3):δ1.1(t,3H,CH3),1.3(t,3H,CH3),1.6(m,3H),1.9(m,1H),2.2(m,2H),2.5(m,1H),2.7(m,1H),2.9(app d,3H,NHCH3),3.1(q,2H,CH2),3.2(m,1H),3.3(m,1H),3.6(m,1H),4.0(s,3H,OCH3),6.1(s,1H,Har),6.8(br s,1H,Har),8.1(br s,NH),8.5(s,1H,NH).13C NMR(75MHz,CDCl3): Δ 8.2, 14.9, 21.2, 29.0, 29.9, 40.5, 47.8, 49.5, 53.7, 56.9, 61.0, 92.1, 110.2, 111.9, 136.1, 150.0, 162.2, 164.0, expected molar weight [ C18H29N3O4S]: 383.2, observed molar weight 384.5[ M + H+]。
Example 3: stereoisomers of compound 102 (compounds 103 and 104), and 4-Aminosulpride derivatives
Compounds 105 to 110).
A) The method comprises the following steps Synthesis of ((S) -4-methylamino N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (Compound 103)
((S) -4-amino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (11.1g) was suspended in N, N-dimethylformamide dimethyl acetal (33mL) and stirred at 90 ℃ for 2 h. The reaction mixture was cooled to room temperature and NaBH was added portionwise4(4g) In that respect The mixture was stirred at room temperature for 1 h. Addition of saturated NaCHO3(50mL) to quench the reaction and extract the resulting suspension with dichloromethane (2X50 mL). The organic phase was washed with brine, dried, filtered and the solvent removed under reduced pressure. Purifying the residue by column chromatography with CH2C12/MeOH/NH3The elution gave the product as a white solid which was further purified by recrystallization from acetone (5.3 g).
1H NMR(400MHz,DMSO-d6):δ1.1(2t,2X3H,CH3),1.5(2,1H)1.6(m,2H),1.8(m,1H),2.1(m,1H),2.3(m,2H),2.5(t,1H),2.6(m,1H),2.7(m,1H),2.9(t,3H),3.1(3,2H),3.2(m,2H),3.3(m,3H),3.5(m,1H),4.0(s,3H,OCH3),6.3(s,1Har),6.6(m,1Har),8.1(m,1H,NH),8.3(s,1H,NH).13C NMR(100MHz,DMSO-d6): δ 7.56, 14.51, 23.05, 28.54, 30.39, 41.64, 47.90, 48.77, 53.62, 56.79, 62.36, 94.45, 109.94, 111.63, 135.68, 151.48, 163.14, 163.82, expected molar weight [ C18H27N3O4S]383.2, observed molar weight 384.4[ M + H+]。
B) The method comprises the following steps Synthesis of ((R) -4-methylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (Compound 104)
((S) -4-amino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (11.2g) was suspended in N, N-dimethylformamide dimethyl acetal (33mL) and stirred at 90 ℃ for 2 hours. The temperature was lowered to 70 ℃ and NaBH was added in an amount of 1g per batch at 20 minute intervals4(4g) In that respect After the addition was complete, the reaction mixture was further stirred at 90 ℃ for 1 hour. The reaction mixture was cooled in an ice bath and purified by addition of 150mL of saturated NaHCO3To quench the reaction. By CH2Cl2(5X50mL) the resulting solution was extracted and the combined organic extracts were washed with Na2SO4And drying. Purification was by column chromatography with 10% MeOH/CH2Cl2Elution afforded 7.9g of a white solid.
1H NMR(300MHz,CDCl3):δ1.2(t,3H,CH3),1.3(t,3H,CH3),1.7(m,1H)1.8(m,2H),1.9(m,1H),2.3(m,2H),2.7(m,1H),2.9(m,1H),2.9(d,1H),3.1(q,2H),3.3(m,2H),3.7(m,1H),4.0(s,3H,OCH3),6.1(s,1Har),6.8(m,1Har) 8.1(m, 1H, NH), 8.6(s, 1H, NH)18H27N3O4S]383.2, observed molar weight 384.2[ M + H [)+]。
C) The method comprises the following steps Synthesis of (4-dimethylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (Compound 105)
4-methylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (500mg) was stirred in 10mL of formic acid at 30 ℃ for 21h while NaBH4(8 eq) was added in two portions and washed with aqueous NaOH to give 408mg of compound 105.
1H NMR(400MHz,CDCl3):δ1.2(t,3H,CH3s),1.7(m,1H),1.8(m,2H),1.9(m,1H),2.2(m,2H),2.7(m,1H),3.2(m,1H),3.3(m,1H),3.4(q,2H),4.0(s,3H,OCH3),6.8(s,1Har),8.0(s,1H,NH)8.8(s,1H).13C NMR(100MHz,CDCl3): δ 7.38, 14.21, 22.96, 28.40, 41.24, 46.14, 48.39, 53.66, 56.11, 62.19, 104.94, 118.52, 126.17, 136.07, 157.93, 161.56, 163.79, expected molar weight [ C19H31N3O4S]397.2, observed molar weight 398.2[ M + H ]+]。
D) The method comprises the following steps Synthesis of (4-ethylmethylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (Compound 106)
4-methylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (500mg) was stirred in 6mL of 1, 2-dichloromethane, sodium triacetoxyborohydride (1g) and acetaldehyde (219uL) were added and stirred at room temperature for 17 hours. The reaction was quenched by addition of aqueous NaOH, and the product was extracted into dichloromethane and purified by column chromatography to afford 98mg of compound 106.
1H NMR(400MHz,CDCl3):δ1.2(m,6H,2CH3s),1.6(m,1H),1.7(m,2H),1.9(m,1H),2.2(m,2H),2.6(m,1H),2.9(m,1H),3.1(q,1H),3.3(m,2H),3.5(q,1H),3.8(m,1H)4.0(s,3H,OCH3),6.8(s,1Har),8.0(s,1H,NH)8.8(s,1H).13C NMR(100MHz,CDCl3):δ7.36,12.84,23.00,28.42,41.27,42.99,48.12,52.30,53.70,56.16.106.05,126.41,130.05,142.41,157.554,157.54,161.48, 163.90 expected molar weight [ C ]20H33N3O4S]411.3, observed molar weight 412.3[ M + H [)+].
E) The method comprises the following steps Synthesis of (4-ethylamino N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (Compound 107)
(Ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (500mg) was stirred in 6mL of 1, 2-dichloroethane and 0.4mL of acetic acid. The mixture was cooled on an ice bath and 1.15g of sodium triacetoxyborohydride was added. The mixture was stirred at room temperature overnight. The reaction was quenched by addition of aqueous NaOH, the product extracted into dichloromethane and purified by column chromatography, recrystallization from acetone/MTBE to afford 309mg of compound 107.
1H NMR(400MHz,CDCl3):δ1.1(br t,3H,CH3),1.3(t,3H,CH3),1.4(t,3H,CH3),1.5-1.8(m,5H),1.8(m,1H),2.2(m,2H),2.7(m,1H),2.9(m,1H),3.1(q,2H),3.3(m 2H),3.7(m,1H),4.0(s,3H,OCH3),6.1(s,1Har),6.7(s,1Har),8.1(s,1H,NH)8.6(s,1H).13C NMR(100MHz,CDCl3): Δ 7.34, 14.17, 22.96, 28.47, 37.99, 41.35, 48.00, 49.82, 53.70, 55.80, 62.38, 93.35, 110.89, 111.91, 136.76, 150.76, 162.90, 164.29, expected molar weight [ C19H31N3O4S]397.2, observed molar weight 398.2[ M + H ]+]。
F) The method comprises the following steps Synthesis of (4-isopropylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (Compound 108)
(Ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (500mg) was stirred in 6mL of DMF and 0.12mL of acetone. The mixture was cooled on an ice bath and 0.3mL TFA was added followed by 441mg sodium triacetoxyborohydride. The mixture was stirred at 40 ℃ overnight. The reaction mixture was poured into aqueous NaOH, and the product was extracted into dichloromethane and purified by column chromatography to give 550mg of compound 108.
1H NMR(400MHz,CDCl3):δ1.1(br t,3H,CH3),1.2(t,3H,CH3),1.3(t,6H,CH3),1.6(m,2H),1.7(m,2H),1.9(m,1H),2.2(m,1H),2.6(m,1H),2.9(m,1H),2.1(q,2H),3.2(m,2H),3.7(m,1H),4.0(s,3H,OCH3),6.1(s,1Har),6.7(s,1Har),8.0(s,1H,NH)8.6(s,1H).13C NMR(100MHz,CDCl3): Δ 7.36, 22.45, 23.02, 28.48, 41.35, 44.15, 49.95, 53.74, 55.80, 93.65, 111.83, 136.69, 150.03, 162.87, 164.33 expected molar weights [ C20H33N3O4S]411.2, observed molar weight 412.2[ M + H [)+]。
G) The method comprises the following steps Synthesis of (4-N-propylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (Compound 109)
(Ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (500mg) was stirred in 6mL of 1, 2-dichloroethane and 0.3mL of propionaldehyde. Sodium triacetoxyborohydride (1.2g) was added in two portions at 10 minute intervals, and the mixture was stirred overnight. The reaction mixture was poured into aqueous NaOH and the product was extracted into ethyl acetate and purified by column chromatography to give 518mg of compound 109.
1H NMR(400MHz,CDCl3):δ1.1(br t,3H,CH3),1.2(t,3H,CH3),1.3(t,6H,CH3),1.6(m,2H),1.7(m,2H),1.9(m,1H),2.2(m,1H),2.6(m,1H),2.9(m,1H),2.1(q,2H),3.2(m,2H),3.7(m,1H),4.0(s,3H,OCH3),6.1(s,1Har),6.7(s,1Har),8.0(s,1H,NH)8.6(s,1H).13C NMR(100MHz,CDCl3): Δ 7.36, 22.45, 23.02, 28.48, 41.35, 44.15, 49.95, 53.74, 55.80, 93.65, 111.83, 136.69, 150.03, 162.87, 164.33 expected molar weights [ C20H33N3O4S]411.2, observed molar weight 412.2[ M + H [)+]。
H) The method comprises the following steps Synthesis of (4-benzylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (Compound 110)
(Ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide (500mg) was stirred in 7mL of DMF and 1.25mL of benzaldehyde and 1mL of TFA. Sodium triacetoxyborohydride (3.5g) was added in two portions and the mixture was stirred at 40 ℃ overnight. The reaction mixture was poured into aqueous NaOH and the product was extracted into dichloromethane and purified by column chromatography to give 366mg of compound 110.
1H NMR(400MHz,CDCl3):δ1.2(t,3H,CH3),1.2-1.3(3,3H,),1.5-1.8(m,3H),1.8-2.0(m,1H),2.3(m,2H),2.6(br s,1H),2.9(m,1H),3.1-3.3(m,1H),3.7(m,1H),3.8(s,3H),4.5(br s,2H),3.7(m,1H),4.0(s,3H,OCH3),6.1(s,1Har),7.4(m,5H),8.0(s,1H,NH)8.6(s,1H).13C NMR(100MHz,CDCl3): δ 7.36, 14.20, 22.91, 28.5, 41.32, 47.52, 50.03, 53.65, 55.77, 62.32, 94.62, 111.36, 112.24, 126.95, 128.97, 136.59, 137.43, 150.53, 162.69, 1664.15 the expected molar weight [ C24H33N3O4S]459.2, observed molar weight 460.2[ M + H [)+]。
Example 4: membrane permeability of Compound 102
The membrane permeability of 4-methylamino-N- ((1-ethyl-2-pyrrolidinyl) methyl) -5- (ethylsulfonyl)) -2-methoxybenzamide) (compound 102) was determined by using the PAMPA assay at pH5 and 7.4. Specifically, 10mM control ranitidine solutions (3.5 mg in 1mL DMSO), propanol (2.9 mg in 1mL DMSO), N-methyl amisulpride (3.3 mg in 0.8mL DMSO), and amisulpride (3.4 mg in 0.9mL DMSO) were prepared. Diffusion across the Pion PAMPA membrane was measured at pH5 and pH7.4, as shown in table 1, respectively.
Table 1: the permeability of compound 102, amisulpride, propranolol, and ranitidine across PAMPA membranes at pH5 and 7.4.
Example 5: binding of Compound 102 to the dopamine D2 receptor (cell-based assay)
Determination of Compound 102 binding to dopamine D in cell-based assays2The ability of the receptor. Mixing dopamine D2Recipient cells were seeded in a 96-well plate with a semi-black clear bottom. At a density of 15,000 cells/well to a volume of 25 μ L, it was incubated overnight. A solution of calcium 5 dye in HEPES-buffered HBSS (Hanks' balanced salt solution) was prepared and 10. mu.L was added to each well and the mixture was allowed to stand at 37 ℃ for 1 hour. After equilibration, 5 μ L of test compound and control were added to the wells and incubated at room temperature for 10 minutes. Fluorescence was measured every 1.52 seconds. After 20 seconds 10. mu.L of dopamine (in EC) was added80At concentration), fluorescence was monitored for 2 minutes with an excitation wavelength of 452nm and an emission wavelength of 525 nm. Cell-based IC of Compound 10250Value and known dopamine D2The inhibitors risperidone, amisulpride and clozapine are collectively listed in table 2.
Table 2: compound 102, risperidone, amisulpride, and clozapine relative to dopamine D2IC of receptor50Values (cell-based assays).
2Example 6: binding of Compound 102 to dopamine D receptor (membrane preparation)
Examination of Compound 102 binding to dopamine D in Membrane preparation2The ability of the receptor. From dopamine D2Recipient cells were removed from the medium and washed with PBS. Lysis buffer (250mM sucrose, 1nM EDTA, 10mM Tris HCl buffer pH7.2 plus protease inhibitor) was added and the cells were scraped off using a plate scraper. Cells were homogenized in a glass homogenizer by 20 manual up-and-down strokes. Removing intact cells, nuclei, and cell debris by centrifuging the homogenate at 500Xg for 10 minutes at 4 deg.C, removing the supernatant, andthe particles were resuspended in assay buffer.
Preparing a film with3H-spiperone is incubated together until equilibrium. The bound product was separated from free radioligand using a Packard Filtermate Harvester and glass filter plates. Radioactivity was measured using a Packard Topcount. 20 μ L of D 220 μ L in binding buffer in membrane and non-binding 96-well plates3H spiroperone was mixed with 10. mu.L of test compound or reference ligand and incubated < 120 min. Prior to filtration, the 96-well harvest filter plates were coated with 0.33% polyethyleneimine for 30 minutes and then washed with assay buffer. The binding reaction was transferred to a filter plate and washed three times with wash buffer, dried, added with scintillator, and counted for radioactivity on Topcount NXT.
0.1nM at concentrations of 1000, 100, 10, 1, 0.1, and 0.01nM are used3 Compound 102, risperidone, amisulpride and clozapine were tested in triplicate for H spiroperone. IC of the film-based assay50The values are shown in table 3.
Table 3: compound 102, risperidone, amisulpride, and clozapine relative to dopamine D2IC of receptor50Values (membrane based test).
2 3Example 7 compounds 102 and 103 are useful as antagonists of various CNS receptors (dopamine D, α 2 epinephrine,
2aand 5-HT receptor) (Table 4)
Table 4: IC50 and Ki values for compound 102(LB102) and compound 103(LB103) relative to various CNS receptors in cell-based assays.
Example 8: new object identification (NOR) assays demonstrate the utility of Compounds 102 and 103
The utility of compounds 102 and 103 was evaluated in rats in a New Object Recognition (NOR) assay, a well-known model that recapitulates the cognitive and negative aspects of the PANSS scale of schizophrenia. In this experiment, animals were treated for several weeks with low doses of phencyclidine (PCP) to impair the ability of rats to discriminate between new and familiar objects. Generally, like humans, rats spend more time exploring a new object than familiar objects. The utility in this study is demonstrated by the ability of the test treatment to restore normal brain function, shown by reversal of PCP damage.
In this NOR study, the utility of compounds 102 and 103 was compared to the known antipsychotic drugs amisulpride and risperidone to evaluate the normal differentiation between new and familiar object exploration in rats that restored PCP treatment. Rats (n-10/group) were dosed intraperitoneally twice daily with 2mg/kg (i.p., b.i.d.) for 7 days, followed by 7 days without drug. Cognitive assays were performed at 3 hours after administration of compounds 102, 103, and amisulpride, and at 30 minutes after administration of risperidone, under various PO dosing test agents. The time to explore new objects was determined for test subjects in a subchronic PCP NOR study (n-10/group) performed on rats. The difference in exploration time between the new (Tnovel-) and familiar (Tfoamiar) objects is shown in FIG. 1A (: p < 0.05; and: p < 0.01). Fig. 1B shows the discrimination index of the NOR study obtained by equation 1 below:
identification index ═ (time spent exploring new object-time spent exploring familiar object)/total exploration time) (equation 1)
Figures 1A and 1B show that all doses of compounds 102(Cpd 102) and 103(Cpd 103), except one, add to the difference between new and familiar object exploration times in a manner consistent with the currently used antipsychotic drugs amisulpride and risperidone.
In the NOR study shown in figures 1A and 1B, compounds 102 and 103 were able to restore the known object-finding behavior in rats treated with PCP to a level similar to that of untreated rats and to an equivalent level to the values obtained with the known antipsychotic drugs amisulpride and risperidone.
Example 9: amphetamine-induced locomotor activity (LMA) assay shows the utility of compounds 102 and 103
The utility of compounds 102 and 103 was studied in rats in the amphetamine-induced locomotor activity (LMA) assay, which is a measure of the positive aspect of the PANSS scale. In the LMA assay, rats were given amphetamine (Amp, 1mg/kg, s.c.) causing excessive movement, and the distance each rat traveled was monitored in a cage with a sensor. Rats given amphetamine alone tend to show hyperactivity, whereas rats given antipsychotic drugs show more normal, calmer activity.
In this LMA study, compounds 102(Cpd 102, 30mg/kg) and 103(Cpd 103, 30mg/kg), amisulpride (30mg/kg) and risperidone (1mg/kg) were administered orally in groups of 10 rats. Amisulpride-risperidone was administered 6 hours after administration of compounds 102 and 103 and 1 hour before the assay, and the distance traveled within one hour was determined. The endpoint of the study was the total walking distance (the distance each animal traveled in the cage). The total walking distance data from this amphetamine-induced LMA study is summarized in figure 2 (: p < 0.01;: p < 0.05).
In the LMA study in rats, as shown in figure 2, the normalized amphetamine overactivity of compound 102(Cpd 102) was statistically superior to amisulpride (p < 0.05), and the normalized amphetamine overactivity of compound 103(Cpd 103) was statistically indistinguishable from amisulpride (p < 0.01).
Example 10: compounds 102, 103, and 104 with 5-HT7Binding of receptors
At 1X 10-7To 3X 10-10Measuring binding of Compounds 102, 103, and 104 to 5-HT at concentration ranges of M7And measuring the ability of the calcium-sensitive fluorescent indicator to express 5-HT7Replacement in the cell of (1). From this experiment, K was found for compound 102(LB-102, filled circle, dotted line B, FIG. 3)iAt 31nM, and amisulpride (LB101, filled circle, dotted line A, FIG. 3) at 106 nM. Compound 103 (the S enantiomer of compound 102) was unexpectedly a stronger conjugate (binder) to the dopamine receptor than compound 104 (the R enantiomer of compound 102), the binding of compound 104 (the R enantiomer of compound 102) providing a K of 16nMi(LB104, filled circle, dotted line D, FIG. 3), and K for compound 103 (S enantiomer of compound 102) (LB103, filled triangle, dotted line C, FIG. 3)iIs > 1,000 nM. Unexpectedly, the R enantiomer of amisulpride (ami) (R), filled circle, dotted line a, fig. 4) shows a lower K than the S enantiomer of amisulpride (ami (S), filled circle, dotted line C, fig. 4)i. K of racemic mixture of amisulpride (amic (rac), filled circle, dotted line B, FIG. 4)iLess than the R enantiomer of amisulpride but greater than the S enantiomer of amisulpride.
Reference to the literature
The references listed below and all references cited in the specification are hereby incorporated by reference in their entirety as if fully set forth herein.
1) H.y.meltzer and s.s.stahl, "dopamine hypothesis of schizophrenia-Review (The dopaminehydrothesis of schizophrenia-a Review)," communique of schizophrenia (schizoph. fill.), 1976, 2, 19-76.
2) J.j.joye and j.h.meador-Woodruff, "link D2 receptor family to neuronal circuits in the human brain: the insight into Schizophrenia (Linking the Family of D2 Receptors to neuronal circuits in Human Brain: insight into Schizophrania), "neuropsychopharmacogenomics", 1997, 16, 1444-.
3)S.Wulff,L.Hageman Pinborg,C.Svarer,L.Jensen,M.Nielsen, p.allerup, n.bak, h.rasmussen, e.frandsen, e.rostrup, and b.odingThe striatum D2/3Binding Potential of Drug-naive schizophrenic patients correlates with treatment outcome (stratial D2/3Binding Potential in Drug-First-Episode Schizophranilia PatientsCorrelated with Treatment Outcome), "Schizophrenia Bulletin (Schizophranilia Bulletin), 2015, 41, 1143-.
4) Roth, d.j.sheffler, and w.k.kroeze, "magic shotgun and magic bullet: selective Non-Selective Drugs for Mood Disorders and Schizophrenia (Magic Shotguns Versus Magic Bullets: Selectively Non-Selective Drugs for food Disorders and Schizophrania), "Nature Reviews Drug Discovery (Nature Reviews Drug Discovery), 2004, 3, 353-.
5) M. Thominet, J.Acher, and J. -C.Monier, "Derivatives of 4-Amino-5-alkylsulfonyl n-acylamides (Derivatives of 4-Amino-5-Alkyl Sulphenyl amides)," U.S. Pat. No. 4,401,822, filed 10/9/1981 (granted 30/8/1983).
6) H.Shoemaker, Y.Claustre, D.Fage, L.Rouquier, K.Chergui, O.Curet, A.Oblin, F.Gonon, J.Benavides, and B.Scatton, "Neurochemical Characteristics of Amisulpride, Atypical Dopamine D2/D3Receptor antagonists with Presynaptic and borderline Selectivity (Neurochemical Characteristics of Amisulpridde, An Experimental Dopamine D2/D3Receptor Anagonist with bouth Presynaptic and Limbic Selectivity)," J.Pharmacol.Exp.Ther., 1997, 280, 83-97.
7) A.a. abbas, p.b.hedlund, X-p.huang, t.b.tran, h.y.meltzer, and b.l.roth, "amisulpride is a potent5-Ht7 antagonist: the Relevance of Antidepressant effects In Vivo (Amisulpride Is aPotent5-Ht7 Antagonist: Relevance for antidepressants Actions In Vivo), "Psychopharmacology (Psychopharmacology), 2009, 119-128.
8) Jafari, f.fernandez-Enright and x. -f.huang, "Structural Contributions of antipsychotics to their Therapeutic profile and Metabolic Side Effects (Structural controls of antibacterial Drugs to Therapeutic Profiles and Metabolic Side Effects)," journal of neurochemistry (j.neurochemistry), 2012, 120, 371- "384.
9)J.N.Dos Santos Pereira,S.Tadjerpisheh,M.Abu Abed,A.R.Saadatmand,B.Weksler,I.A.Romero,P.-O.Couraud,J.And m.v. tzvetkov, "The poor membrane permeability antipsychotics Amisulpride and Sulpride Are substrates of The SLC22 Family of Organic Cation Transporters (The poorly membrane Permeable antibacterial Drugs Amisulpride and Sulpride Are substrates of The Organic Cation Transporters from The SLC22 Family)," journal of AAPS (The AAPSJournal), 2014, 16, 1247-.
10) Neill, s.barnes, s.cook, b.grayson, n.f.idris, s.l.mclean, s.snigdha, l.rajagopal and m.k.harte, "animal models of cognitive dysfunction and negative symptoms of schizophrenia: concerns NMDA Receptor Antagonism (antibody Models of cognitive dyefunction and Negative symptoms of Schizophrenia: Focus on NMDA Receptor Antagonism), "Pharmacology and Therapeutics (Pharmacology & Therapeutics), 2010, 128, 419-432.
11) Neill, m.k.harte, p.m.haddad, e.s.lydall, and d.m.dwyer, "acute and chronic effects of Nmda receptor antagonists in rodents, correlation with negative symptoms of schizophrenia: in connection with human transformation (Acute and viral Effects of Nmda Receptor antibodies in Rodents, Relevance to Negative sym stamps of Schizophrania: A relative Link to humans), "European neuropsychological pharmacology (2014, 24, 822-.
12) Neill, b.grayson, b.kiss, i.gyrty a, p.ferguson and n.adham, "Effects of the Novel Antipsychotic drug kalilazine On Cognitive deficits and negative Symptoms in Rodent models of Schizophrenia Symptoms (Effects of Cariprazine, a Novel antipathology, On Cognitive deficits and synergistic models of Schizophrenia Symptomatology)," European neuropsychology (European neuropsychology), 2016, 26, 3-14.
Claims (27)
1. A method of antagonizing one or more serotonin receptors in a subject, comprising administering to the subject a therapeutically effective amount of a compound having the structure shown in formula I and/or the R isomer of amisulpride, alone or in combination with other CNS active agents:
including pharmaceutically acceptable salts and stereoisomers thereof, wherein:
x and Z are the same or different and are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, aralkyl, heteroaralkyl, and heteroaryl, optionally the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaralkyl, and heteroaryl are further substituted with one or more substituents selected from halogen such as chlorine, bromine, and fluorine, amine, hydroxyl, carboxylic acid, nitro, carbonyl, and other alkyl and aryl groups defined herein; with the proviso that at least one of X and Z is not hydrogen.
2. A method of treating one or more conditions responsive to modulation of one or more serotonin receptors in a subject, comprising administering to the subject a therapeutically effective amount of a compound having the structure shown in formula I and/or the R isomer of amisulpride, either alone or in combination with other CNS active agents:
including pharmaceutically acceptable salts and stereoisomers thereof, wherein R1Is that And X and Z are the same or different and are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, aralkyl, heteroaralkyl, and heteroaryl, optionally the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, aralkyl, heteroaralkyl, and heteroaryl are further substituted with one or more substituents selected from halogen such as chlorine, bromine, and fluorine, amine, hydroxyl, carboxylic acid, nitro, carbonyl, and other alkyl and aryl groups defined herein; with the proviso that at least one of X and Z is not hydrogen.
3. A method of treating one or more disorders associated with abnormal serotonin levels in the brain of a subject, comprising administering to the subject a therapeutically effective amount of a compound having the structure shown in formula I and/or the R isomer of amisulpride, alone or in combination with other CNS active agents:
including pharmaceutically acceptable salts and stereoisomers thereof, wherein:
x and Z are the same or different and are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, aryl, aralkyl, heteroaralkyl, and heteroaryl, optionally the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaralkyl, and heteroaryl are further substituted with one or more substituents selected from halogen such as chlorine, bromine, and fluorine, amine, hydroxyl, carboxylic acid, nitro, carbonyl, and other alkyl and aryl groups defined herein; with the proviso that at least one of X and Z is not hydrogen.
8. The method of any one of the preceding claims, wherein X and Z are the same or different and are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, and heteroaryl, optionally further substituted with one or more substituents selected from halogen such as chloro, bromo, and fluoro, amine, hydroxy, carboxylic acid, nitro, carbonyl, and other alkyl and aryl groups defined herein; with the proviso that at least one of X and Z is not hydrogen.
9. A compound according to any preceding claim, wherein X is H.
10. A compound as claimed in any one of the preceding claims, wherein X ═ H and Z ═ CH3。
11. The method of any of the preceding claims, wherein the disorder or condition is a psychiatric disease.
12. The method of claim 11, wherein the psychiatric disorder is schizophrenia.
13. The method of any one of the preceding claims, wherein the method further comprises administering to the subject a therapeutically effective amount of another agent.
14. The method of any of the preceding claims, wherein the disorder or condition is depression.
15. The method of any of the preceding claims, wherein the disorder or condition is bipolar disorder.
16. The method of any of the preceding claims, wherein the disorder or condition is tourette's syndrome.
17. The method of any of the preceding claims, wherein the disorder or condition is a schizoaffective disorder.
18. The method of any one of the preceding claims, wherein the disorder or condition is Parkinson's disease.
19. The method of any one of the preceding claims, wherein the disorder or condition is alzheimer's disease.
20. The method of any one of the preceding claims, wherein the disorder or condition is an oppositional defiant disorder.
21. The method of any of the preceding claims, wherein the disorder or condition is personality disorder.
22. The method of any of the preceding claims, wherein the disorder or condition is childhood schizophrenia.
23. The method of any of the preceding claims, wherein the disorder or condition is dysthymia.
24. The method of any of the preceding claims, wherein the disorder or condition is refractory schizophrenia.
25. The method of any one of the preceding claims, wherein the serotonin receptor is 5-HT2aOr 5-HT7A receptor.
26. The method of any of the preceding claims, wherein the disorder or condition is chronic fatigue syndrome.
27. The method of any of the preceding claims, wherein the disorder or condition is predominantly a negative symptom of schizophrenia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762508263P | 2017-05-18 | 2017-05-18 | |
US62/508,263 | 2017-05-18 | ||
PCT/US2018/033552 WO2018213813A2 (en) | 2017-05-18 | 2018-05-18 | Psychotropic agents and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110944630A true CN110944630A (en) | 2020-03-31 |
Family
ID=64274762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880048781.8A Pending CN110944630A (en) | 2017-05-18 | 2018-05-18 | Psychotropic agents and uses thereof |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3625212A4 (en) |
CN (1) | CN110944630A (en) |
WO (1) | WO2018213813A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11377421B2 (en) | 2016-11-28 | 2022-07-05 | Lb Pharmaceuticals Inc. | Psychotropic agents and uses thereof |
JP6968899B2 (en) | 2016-11-28 | 2021-11-17 | エルビー・ファーマシューティカルズ・インコーポレイテッド | Psychotropic drugs and their use |
CN117074579B (en) * | 2023-10-16 | 2023-12-22 | 江苏东科康德药业有限公司 | Analysis method of related substances of amisulpride oral solution |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6069165A (en) * | 1996-09-18 | 2000-05-30 | Synthelabo | Pharmaceutical compositions containing amisulpride and their therapeutic applications |
US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US20100105755A1 (en) * | 2008-09-12 | 2010-04-29 | Auspex Pharmaceuticals, Inc. | Substituted benzamide modulators of dopamine receptor |
CN110248655A (en) * | 2016-11-28 | 2019-09-17 | Lb制药公司 | Psychopharmaceutical and application thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4210660A (en) * | 1978-12-20 | 1980-07-01 | Yamanouchi Pharmaceutical Co., Ltd. | Benzamide derivatives |
BR112020011189A2 (en) * | 2017-12-05 | 2020-11-17 | Sunovion Pharmaceuticals Inc. | non-racemic mixtures and uses thereof |
-
2018
- 2018-05-18 EP EP18801735.4A patent/EP3625212A4/en active Pending
- 2018-05-18 CN CN201880048781.8A patent/CN110944630A/en active Pending
- 2018-05-18 WO PCT/US2018/033552 patent/WO2018213813A2/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6069165A (en) * | 1996-09-18 | 2000-05-30 | Synthelabo | Pharmaceutical compositions containing amisulpride and their therapeutic applications |
US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US20100105755A1 (en) * | 2008-09-12 | 2010-04-29 | Auspex Pharmaceuticals, Inc. | Substituted benzamide modulators of dopamine receptor |
CN110248655A (en) * | 2016-11-28 | 2019-09-17 | Lb制药公司 | Psychopharmaceutical and application thereof |
CN111233731A (en) * | 2016-11-28 | 2020-06-05 | Lb制药公司 | Psychotropic agents and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2018213813A8 (en) | 2019-11-07 |
WO2018213813A3 (en) | 2019-12-12 |
EP3625212A4 (en) | 2021-03-31 |
EP3625212A2 (en) | 2020-03-25 |
WO2018213813A2 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111233731B (en) | Psychotropic agents and uses thereof | |
AU2002237654B2 (en) | Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | |
BRPI0613491A2 (en) | piperazine-piperidine antagonists and 5-ht1a receptor agonists | |
JP2021503443A (en) | Antagonist of muscarinic acetylcholine receptor M4 | |
JP2020526557A (en) | Antagonist of muscarinic acetylcholine receptor M4 | |
US11377421B2 (en) | Psychotropic agents and uses thereof | |
CN110944630A (en) | Psychotropic agents and uses thereof | |
JP2020530451A (en) | Antagonist of muscarinic acetylcholine receptor M4 | |
JP2020537667A (en) | Antagonist of muscarinic acetylcholine receptor M4 | |
SK9002001A3 (en) | 5ht1 antagonists for antidepressant therapy | |
KR20200097694A (en) | Novel alkoxyamino derivatives for treating pain and pain related conditions | |
WO2015014256A1 (en) | Substituted heteroaryl compounds and methods of use thereof | |
US20240158347A1 (en) | Psychotropic agents and uses thereof | |
TW202100149A (en) | Psychotropic agents and uses thereof | |
TW202023540A (en) | Psychotropic agents and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40016096 Country of ref document: HK |